Furthermore, elements of the RAS have become cardiovascular pharmacotherapy targets; angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) are RAS blockers commonly used to manage hypertension and have been shown to reduce SNS activity [63, 154]. The gene discussed is ACE; the disease is hypertensive disorder.